Innovative IT solutions to develop personalized cancer treatment.
Oslo Cancer Cluster and NCE Smart Energy Markets, together with European clusters in medicine and IT (see list below), has been managing a Horizon 2020 EU project driving Personalized Medicine Innovation, called PERMIDES. The project ended in the last part of 2018. The project matched small and medium enterprises (SMEs) from the IT and the biopharma sector for joint innovation projects.
Allocated funds were 45 million NOK, of which 34 million NOK were earmarked for SMEs in the clusters.
Stay tuned for an update on the results of the PERMIDES project.
90 innovation projects between IT and biotechs with funding through an innovation voucher system
120 IT companies and biotech companies have benefited from technology transfer activities
75 enterprises have participated in networking conferences at regional and European level
100 companies have placed their profile in a semantic matchmaking portal – the PERMIDES platform
Resuts of the first call 2017
PERMIDES has turned out to be of great interest to both the biopharma and the IT sector. With the first cut-off date in mid-May 2017, a total of 46 applications with an overall volume of more than € 2.5 million have been submitted for innovation projects, each project involving a biopharmaceutical SME and at least one IT SME.
22 of these 46 applications have been awarded for funding with an overall funding amount of more than € 1.25 million. In this first application round, project proposals were submitted for e.g. the development of intelligently networked sensors for special therapies, innovative interfaces for medical wearables, as well as novel computer-based methods for cancer research.
Get an overall glance of the wide range of projects RIGHT HERE
Results from the second call 2018 will be published shortly.